Johnson & Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates

Johnson & Johnson (NYSE:JNJ) is reportedly considering selling its stroke care unit, Cerenovus, in a deal that could value the business at more than $1 billion.The move aligns with the company’s ongoing efforts to streamline its medical technology division following a series of acquisitions.The healthcare giant has engaged advisers to gauge interest from private equity firms and strategic buyers.Also Read: Johnson & Johnson’s MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: AnalystMonday’s Financial Times report, citing sources, indicates that Cerenovus, which develops surgical tools for stroke treatment, could ...Full story available on Benzinga.comWeiter zum vollständigen Artikel bei Benzinga Weiter zum vollständigen Artikel bei Benzinga